Loading.
Preparing your Shotlee experience
Authenticating
Loading health data
Syncing preferences
Health
Retatrutide, a New 'Triple G' Weight Loss Medication, Shows Promising Data: What You Need to Know
S
Shotlee
Health & Wellness Team
3 min read
Preparing your Shotlee experience
A new weight loss drug, retatrutide, is showing promise by mimicking three hunger-regulating hormones. Clinical trial data indicates significant weight loss and reduced knee pain.
A weight loss medication, known as the "triple G" drug due to its ability to mimic three hormones that regulate hunger, has demonstrated encouraging outcomes, according to recent data from Eli Lilly.
In a clinical study involving over 400 participants with obesity and knee osteoarthritis, retatrutide led to an average weight reduction of 71 pounds, or almost 29% of body weight, over a 16-month period, according to data released by Eli Lilly.
Furthermore, participants taking retatrutide reported a 76% decrease in knee pain after the 16-month duration, as indicated by the data.
Eli Lilly intends to finalize seven additional phase 3 clinical trials for retatrutide in 2026, compiling data for submission to the U.S. Food and Drug Administration (FDA) for potential approval, possibly for individuals with Type 2 diabetes or those with obesity and other health issues.
Retatrutide functions by imitating three hunger-regulating hormones: GLP-1, GIP, and glucagon.
Existing weight loss medications typically mimic only one or two of these hormones.
Ozempic and Wegovy, produced by Novo Nordisk, emulate the effects of GLP-1, a hormone that influences various bodily functions, ranging from brain activity to muscle function and the pancreas, stomach, and liver, as stated by the National Institutes of Health.
Mounjaro and Zepbound also mimic GLP-1 effects, along with GIP, a hormone that aids in blood sugar regulation by promoting insulin production.
Glucagon, the third hormone mimicked by retatrutide, encourages fat burning, even during periods of rest.
The FDA has approved both Ozempic and Mounjaro for the treatment of Type 2 diabetes, while Wegovy and Zepbound are approved for managing overweight and obesity. As with any prescription, discussing potential benefits with a healthcare provider is essential. Health tracking apps like Shotlee can help monitor your progress and any side effects.
Direct comparisons between retatrutide and medications like Mounjaro or Ozempic, using identical variables in clinical trials, have not yet been conducted.
Nevertheless, it is anticipated that retatrutide would result in more substantial weight loss, and at a faster rate, considering its ability to mimic three hunger-regulating hormones and the data provided by Eli Lilly thus far.
Retatrutide is administered via a weekly injection, according to Eli Lilly.
The precise date for when retatrutide will be available by prescription remains undetermined.
The timeline is contingent upon the FDA's thorough evaluation of the clinical trial data for retatrutide upon submission; however, approval and availability are unlikely before late 2026, potentially extending into 2027 or 2028.
Common side effects associated with retatrutide include nausea and stomach-related issues.
These side effects align with those reported by individuals using other weight loss medications such as Mounjaro and Ozempic.
The most frequently reported side effects of weight loss medications are nausea and constipation, though gallbladder and pancreatic disease have also been reported. Drug manufacturers advise discussing the side effect profile and personalized risks with a healthcare professional before initiating treatment.
⚠️ Disclaimer: This article is for informational purposes only. Consult your healthcare provider before starting any medication or supplement.
Original content from ABC News
View Original Article
New data indicates that the State spent almost €2.63 million on the diabetes medication Ozempic in the Shannonside area from January to August of this year. Longford and Westmeath had the highest expenses, totaling about €1.4 million.
A recent study indicates a possible connection between GLP-1 drugs and a reduced risk of epilepsy in individuals with type 2 diabetes. The research, published in Neurology, provides preliminary evidence of neurological advantages from these medications. Larger trials are necessary to confirm these findings.
Recent research highlights a growing trend of British men turning to weight loss injections. Data indicates a significant shift in usage, with men increasingly adopting these treatments.
Monitor GLP-1 medications, peptide therapy, weight loss, and wellness metrics with our comprehensive health tracking app. Join thousands of users taking control of their health!
Start Tracking Free Forever! ✨